Pathfinder Cell Therapy Stock

Pathfinder Cell Therapy Current Liabilities

The Current Liabilities of Pathfinder Cell Therapy (PFND) as of Aug 11, 2026 is 6.89 M USD. In the previous year, Current Liabilities was 5.23 M USD — a change of 31.59% (higher).

Current Liabilities

6.89 MUSD

YoY

31.59%

Last updated:

Current Liabilities of Pathfinder Cell Therapy is 2026 6.89 M USD. Current Liabilities of Pathfinder Cell Therapy was 2025 5.23 M USD. It decreases by 31.59% higher compared to the previous year.
Access this data via the Eulerpool API

Pathfinder Cell Therapy Stock analysis

What does Pathfinder Cell Therapy do? Pathfinder Cell Therapy Inc is a biopharmaceutical company specializing in the development of cell-based therapies. The company was founded in 2018 and is headquartered in Boston, Massachusetts. The founders of Pathfinder Cell Therapy have come together to develop innovative solutions for diseases that cannot be treated by conventional therapies. They believe that cell-based therapies have the potential to dramatically improve the lives of patients by directly addressing the underlying causes of their diseases. Pathfinder Cell Therapy's business model focuses on the development of cell-based therapies for specific diseases. The company works closely with academics, scientists, and clinicians to incorporate the latest knowledge and technologies into the development of new therapies. Pathfinder Cell Therapy has various divisions that focus on the development of cell-based therapies for specific diseases. One focus is on developing therapies for rare genetic diseases that are often difficult to treat. Other divisions focus on the development of therapies for cancer and autoimmune diseases. The company already has several products in development, including a cell-based therapy for the treatment of mucopolysaccharidosis type I (MPS-I), a rare genetic disease in which a specific type of sugar cannot be broken down and accumulates in various organs. Pathfinder Cell Therapy also plans to develop cell-based therapies for other rare genetic diseases such as Fabry disease and Krabbe disease. Another important product of Pathfinder Cell Therapy is a cell-based therapy for the treatment of certain types of cancer. This therapy harnesses the ability of immune cells to recognize and attack cancer cells to mobilize the body in the fight against cancer. This type of therapy is called immunotherapy and has made significant advances in recent years. Pathfinder Cell Therapy is also working on the development of cell-based therapies for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In these diseases, the immune system mistakenly attacks healthy body cells. Cell-based therapies can help reprogram the immune system to only target pathogens and leave healthy cells unharmed. Overall, Pathfinder Cell Therapy aims to develop the next generation of cell-based therapies to treat diseases that have been difficult or impossible to treat in the past. The company has an experienced team of scientists who work closely with doctors and patients to ensure that their therapies can truly improve people's lives. Pathfinder Cell Therapy is still in the development phase, but the company has already made promising progress and is expected to achieve further success in the coming years. Pathfinder Cell Therapy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pathfinder Cell Therapy stock

Current Liabilities of Pathfinder Cell Therapy is 6.89 M USD in 2026.

Current Liabilities of Pathfinder Cell Therapy changed from 5.23 M USD to 6.89 M USD, representing a 31.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Pathfinder Cell Therapy since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Pathfinder Cell Therapy historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Pathfinder Cell Therapy

All Key Metrics — Pathfinder Cell Therapy